Xencor (XNCR) Non-Current Assets (2013 - 2026)
Xencor's (XNCR) quarterly Non-Current Assets came in at $254.0 million in Q1 2026, down 33.76% year-on-year from $383.4 million in Q1 2025, and down 7.87% on a QoQ basis from $275.7 million in Q4 2025.
Xencor (XNCR) Non-Current Assets (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Non-Current Assets data on file, last reported at $254.0 million in Q1 2026.
- On a quarterly basis, Non-Current Assets fell 33.76% year-over-year to $254.0 million in Q1 2026; TTM through Mar 2026 was $1.2 billion, a 13.44% decrease from a year earlier, with the FY2025 full-year figure at $275.7 million, down 26.36% from the prior year.
- Non-Current Assets for Q1 2026 stood at $254.0 million, down from $275.7 million in the prior quarter.
- Over the last five years, Non-Current Assets for XNCR reached as high as $410.3 million in Q3 2024 and fell as low as $167.3 million in Q3 2022.
- Historically, Non-Current Assets has averaged $285.8 million across 5 years, with a median of $275.7 million in 2025.
- On a YoY basis, Non-Current Assets climbed as much as 246.52% in 2022 and fell as far as 58.7% in 2022.
- Year by year, Non-Current Assets stood at $170.9 million in 2022, then jumped by 92.79% to $329.5 million in 2023, then rose by 13.6% to $374.3 million in 2024, then retreated by 26.36% to $275.7 million in 2025, then fell by 7.87% to $254.0 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $254.0 million in Q1 2026, $275.7 million in Q4 2025, and $350.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | 253.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 253.99 Mn |
| Dec 31, 2025 | 275.67 Mn |
| Sep 30, 2025 | 350.37 Mn |
| Jun 30, 2025 | 366.27 Mn |
| Mar 31, 2025 | 383.42 Mn |
| Dec 31, 2024 | 374.34 Mn |
| Sep 30, 2024 | 410.31 Mn |
| Jun 30, 2024 | 271.70 Mn |
| Mar 31, 2024 | 322.00 Mn |
| Dec 31, 2023 | 329.53 Mn |
| Sep 30, 2023 | 207.25 Mn |
| Jun 30, 2023 | 184.56 Mn |
| Mar 31, 2023 | 173.44 Mn |
| Dec 31, 2022 | 170.92 Mn |
| Sep 30, 2022 | 167.27 Mn |
| Jun 30, 2022 | 265.39 Mn |
| Mar 31, 2022 | 351.95 Mn |
| Dec 31, 2021 | 413.84 Mn |
| Sep 30, 2021 | 367.64 Mn |
| Jun 30, 2021 | 214.64 Mn |